ライフサイエンスコーパス: iPS cell

1 stem cells from 2 patients with MPS IH (MPS-iPS cells).

2 S) cells from three subjects with RDEB (RDEB iPS cells).

3 broblasts to induced pluripotent stem cells (iPS cells).

4 alterations that are repeatedly observed in iPS cells.

5 transition from these intermediate stages to iPS cells.

6 regulates reprogramming of fibroblasts into iPS cells.

7 ment and function of Treg cells derived from iPS cells.

8 roid cells differentiated from the corrected iPS cells.

9 ntrol expression of a wide range of genes in iPS cells.

10 ural differentiation of murine P19 and human iPS cells.

11 gram MECs and mouse embryonic fibroblasts to iPS cells.

12 on factors, are significantly less stable in iPS cells.

13 increased stability of many histone mRNAs in iPS cells.

14 ification of myogenic progenitors from human iPS cells.

15 ocyte generation from patient-specific human iPS cells.

16 (iPS) cells with similar properties as mouse iPS cells.

17 s similar to that observed in wild-type (WT) iPS cells.

18 , but also results better genetic quality in iPS cells.

19 roblasts and human amniotic fluid cells into iPS cells.

20 fficient in-frame targeting of MYF5 in human iPS cells.

21 1 improves the generation of mouse and human iPS cells.

22 tecture in neurons differentiated from FXTAS iPS cells.

23 200, that are absent in both fibroblasts and iPS cells.

24 pplication of reprogramming somatic cells to iPS cells.

25 genes, affects the cardiogenic competency of iPS cells.

26 richment is partially maintained in Lsh(-/-) iPS cells.

27 derived from human induced pluripotent stem (iPS) cells.

28 the generation of induced pluripotent stem (iPS) cells.

29 cells and human inducible pluripotent stem (iPS) cells.

30 somatic cells into induced pluripotent stem (iPS) cells.

31 f somatic cells to induced pluripotent stem (iPS) cells.

32 ntiation of ES and induced pluripotent stem (iPS) cells.

33 ) reprogramming to induced pluripotent stem (iPS) cells.

34 adily derived from induced pluripotent stem (iPS) cells.

35 ogrammed to become induced pluripotent stem (iPS) cells.

36 of fibroblasts to induced pluripotent stem (iPS) cells.

37 cient formation of induced pluripotent stem (iPS) cells.

38 pluripotency in partially reprogrammed (pre-iPS) cells.

39 e cells (hHFCs) to induced pluripotent stem (iPS) cells.

40 tine generation of induced pluripotent stem (iPS) cells.

41 somatic cells into induced pluripotent stem (iPS) cells.

42 muscle cells from induced pluripotent stem (iPS) cells.

43 enic competency of induced pluripotent stem (iPS) cells.

44 or copy number variation were identified in iPS cells after the two subsequent clonal events.

45 Here we report that iPS cell and epithelial markers, such as SSEA1 and EpCAM

46 Here, we exploited mutation correction of iPS cells and conserved proteotoxic mechanisms from yeas

47 uced SSEA-1+ cells were purified from ES and iPS cells and could be directed to differentiate into ca

48 urces of genetic and phenotypic variation in iPS cells and establishes their suitability as models of

49 skeletal myogenic progenitors from human ES/iPS cells and highlights their potential for future ther

50 e by days 7-8 of EB development, both in our iPS cells and in R1 cells.

51 rm cell transformation and the generation of iPS cells and indicate that the Hippo pathway constitute

52 etically matched sets of human IVF ES cells, iPS cells and nuclear transfer ES cells (NT ES cells) de

53 tic and transcriptional similarity of ES and iPS cells and to predict the differentiation efficiency

54 es provide an efficient source of autologous iPS cells and, as feeder cells, can also maintain iPS an

55 mRNAs expressed in induced pluripotent stem (iPS) cells and the fully differentiated human foreskin f

56 al Treg cells from induced pluripotent stem (iPS) cells and to determine the potential role of such c

57 Undifferentiated PKD iPS cells, control iPS cells, and embryonic stem cells elaborated primary c

58 oward modeling hematological disorders using iPS cells, and illustrate the hurdles that must be overc

59 has been no report of endoderm-derived human iPS cells, and this has prevented comprehensive comparat

60 ly intermediate state and fully reprogrammed iPS cells, and thus represent some of the earliest known

61 fferentiated cells to form pluripotent stem (iPS) cells, and c-Met activation counteracted the effect

62 onic stem (ES) and induced pluripotent stem (iPS) cells, and we also provide evidence for its extensi

63 Hepatocyte-derived iPS cells appear indistinguishable from hES cells with r

64 Although iPS cells appear molecularly and functionally similar to

65 demonstrate, for the first time, that human iPS cells are able to undergo hematopoiesis that contrib

66 re have been insufficient data to prove that iPS cells are functionally equivalent to human embryonic

67 r cells (NPCs) and neurons suggests that (i) iPS cells are not permissive to HCMV infection, i.e., th

68 iPS cells are similar to human embryonic stem (hES) cell

69 ineered from human induced pluripotent stem (iPS) cells are a powerful system for evaluating the path

70 d from ES cells or induced pluripotent stem (iPS) cells are an intriguing source for stem cell-based

71 Autologous induced pluripotent stem cells (iPS cells) are prone to epigenetic and transcriptional a

72 aims to critically discuss the potential of iPS cells as a new source of cell therapeutics.

73 se and human models and validates the use of iPS cells as a platform to study the underlying cellular

74 human models, thereby validating the use of iPS cells as a platform to study underlying cellular pat

75 candidates for influencing the generation of iPS cells as well as for providing new insights into the

76 However, ADPKD iPS cells as well as somatic epithelial cells and hepato

77 cribe a strategy to genetically modify human iPS cells at 'safe harbor' sites in the genome, which fu

78 ional molecular studies, drug screening, and iPS cell-based platforms for disease modeling.

79 Here, we report that these iPS cells can be differentiated in vivo into functional

80 iPS cells can be differentiated into progenitor T cells

81 ow that, despite some molecular differences, iPS cells can be efficiently differentiated into DE prec

82 papers in this issue, have demonstrated that iPS cells can differentiate into keratinocytes.

83 tablished that the differentiated progeny of iPS cells can effectively reverse failure of a vital org

84 This is done by making the EBs from iPS cells carrying a novel Oct4 reporter (Oct4-MerCreMer

85 ons in protein coding regions in the initial iPS cell clone.

86 globin transgene in beta-thalassemia-patient iPS cell clones meet our safe harbor criteria and permit

87 ng dynamics, but also increases the ratio of iPS cell colonies to total colonies by reducing the freq

88 Undifferentiated PKD iPS cells, control iPS cells, and embryonic stem cells e

89 OBEC3B (also known as A3B) and PIWIL2 in NHP iPS cells correlated with increased L1 mobility and endo

90 required for stem cell renewal and that RDEB iPS cells could be differentiated into both hematopoieti

91 cells have raised uncertainty as to whether iPS cells could generate autologous endodermal lineages

92 We propose that induced pluripotent stem (iPS) cells could be a unique biological resource to dete

93 yonic stem (ES) or induced pluripotent stem (iPS) cells could overcome this hurdle.

94 Experience with human iPS cell culture and sorting via FACS will be of benefit

95 provide evidence for its extension to human iPS cells cultured without feeder cells.

96 ithin mouse ES and induced pluripotent stem (iPS) cell cultures that expresses high levels of transcr

97 The promise of iPS cell derivatives for therapeutic applications is enc

98 Both NT ES cells and iPS cells derived from the same somatic cells contained

99 ractogenesis using induced pluripotent stem (iPS) cells derived from various cataract patients.

100 PS cell lines and, specifically, how similar iPS cell-derived cardiomyocytes (iPS-CMs) are to embryon

101 we demonstrate that mutant titin protein in iPS cell-derived cardiomyocytes results in sarcomere ins

102 another step closer to clinical use of ES or iPS cell-derived cardiovascular progenitors in cardiac r

103 suggesting that GATA1 suppression in ES and iPS cell-derived hematopoietic progenitors may enhance m

104 Here, we examined whether iPS cell-derived hepatocytes have both the functional an

105 tent of neurite shortening and cell death in iPS cell-derived neurons in patients with HD.

106 m patients with HD and patients with HD with iPS cell-derived neurons reduced mitochondrial fragmenta

107 Whether iPS cell-derived neurons will always faithfully recapitu

108 Our study highlights the utility of iPS cell-derived NPCs to elucidate the role of astrocyte

109 Here we present human iPS cell-derived organoids through sequential rounds of

110 iral expression of wild-type PINK1 in mutant iPS cell-derived PINK1 neurons.

111 iPS cell-derived T cells can offer the advantages of avo

112 Importantly, adoptive transfer of iPS cell-derived Treg cells expressing large amounts of

113 e editing in human induced pluripotent stem (iPS) cell-derived neural progenitor cells (NPCs) to repa

114 onal studies using induced pluripotent stem (iPS) cell-derived neuronal cells are needed to validate

115 Instead, induced pluripotent stem (iPS) cell-derived RPE from patients provides us with ear

116 causes synaptic vesicle release deficits in iPS-cell-derived forebrain neurons.

117 TCR-transduced iPS cells developed in vivo responded in vitro to peptid

118 ed closely to those of IVF ES cells, whereas iPS cells differed and retained residual DNA methylation

119 report a novel in vivo system in which human iPS cells differentiate within teratomas to derive funct

120 Importantly, human WT and RDEB iPS cells differentiated in vivo into structures resembl

121 ession of CD3, TCR, CD4, CD25, and CTLA-4 on iPS cell-differentiated Treg cells, which are able to se

122 erapies; however, the majority of current ES/iPS cell differentiation protocols are limited by low yi

123 Furthermore, human ES cell and iPS cell differentiation to cerebral cortex recapitulate

124 Pulsed transgene overexpression, before iPS cell differentiation, hindered cardiogenic outcomes.

125 Re-supplementing AOF2 in iPS cells disrupted such global demethylation and induce

126 Offload of transgenes in engineered iPS cells ensures integrity of cardiac developmental pro

127 Intriguingly, iPS cells exhibited aberrant silencing of imprinted gene

128 d FPC at similar levels, and PKD and control iPS cells exhibited comparable rates of proliferation, a

129 Gene-corrected RDEB iPS cells expressed Col7.

130 This method does not use iPS cell factors and thus differs from cell activation a

131 The induced pluripotent stem (iPS) cell field holds promise for in vitro disease model

132 efficacy of differentially originated human iPS cells for cell therapy.

133 expression levels and support the use of PKD iPS cells for investigating disease pathophysiology.

134 Here, we examined the use of human iPS cells for modeling inherited metabolic disorders of

135 eutic or suicide genes into patient-specific iPS cells for use in cell therapy.

136 several orders of magnitude and facilitated iPS cell formation in as little as 4 days.

137 a well known reprogramming factor, promoted iPS cell formation.

138 The NKX2-5-GFP(+) iPS cells formed cardiomyocytes by numerous induction pr

139 We isolated iPS cells free of transgene sequences from a patient wit

140 Here, we derive ES and iPS cells from a transgenic Oct4 distal enhancer reporte

141 e generation and initial characterization of iPS cells from chimpanzees and bonobos as new tools to e

142 We derived iPS cells from human adult fibroblasts and induced neura

143 muscle insulin resistance by differentiating iPS cells from individuals with mutations in the insulin

144 on would limit derivation and maintenance of iPS cells from patients with DC.

145 We differentiated iPS cells from patients with Parkinson's disease (PD) in

146 for the generation of modified mRNA-derived iPS cells from primary human fibroblasts, focusing on th

147 We created iPS cells from two children with hereditary PAP (hPAP) c

148 bility to generate induced pluripotent stem (iPS) cells from a patient's somatic cells has provided a

149 eadily detected in induced pluripotent stem (iPS) cells from both primate species.

150 Here we generated induced pluripotent stem (iPS) cells from four members of a family in which a fram

151 ficiently deriving induced pluripotent stem (iPS) cells from human and mouse amniocytes, and for main

152 We generated induced pluripotent stem (iPS) cells from individuals with PMDS and autism and use

153 the generation of induced pluripotent stem (iPS) cells from skin fibroblasts taken from three PD pat

154 The generation of induced pluripotent stem (iPS) cells from somatic cells by the ectopic expression

155 sfer, we generated induced pluripotent stem (iPS) cells from three subjects with RDEB (RDEB iPS cells

156 Transgene-free iPS cells generated reproducible beating activity with r

157 ing from random genomic integration, we used iPS cells generated without viruses.

158 on blastocysts and induced pluripotent stem (iPS) cells generated from somatic cell sources are pluri

159 We recently reported efficient iPS cell generation from human fibroblasts using synthet

160 ological mechanisms essential for successful iPS cell generation requires both accurate capture of ce

161 nificantly increases the efficiency of mouse iPS cell generation using the transcription factors Oct4

162 hanism may shed light on the improvements of iPS cell generation.

163 te as a chemical factor capable of promoting iPS cell generation.

164 s are capable of enhancing the efficiency of iPS cell generation.

165 the efficiency of induced pluripotent stem (iPS) cell generation.

166 In this study, we generated murine iPS cells genetically modified with ovalbumin (OVA)-spec

167 Both hPAP and normal iPS cells had human embryonic stem cell-like morphology,

168 Induced pluripotent stem (iPS) cells harbour a reparative potential, and were here

169 rammed to become inducible pluripotent stem (iPS) cells has created enthusiasm for their potential ap

170 ram adult cells to induced pluripotent stem (iPS) cells has now enabled the possibility of patient-sp

171 lizing human induced pluripotent stem cells (iPS cells) has enormous potential to provide improved ce

172 Human iPS cells have been derived mostly from cells originatin

173 Patient-specific iPS cells have been derived not only for disease modelin

174 iPS cells have been found to contain a large number of d

175 ng lung epithelial cells derived from ES and iPS cells have lagged behind similar efforts devoted to

176 Importantly, these iPS cells have only a single integration site in each ce

177 Human induced pluripotent stem (iPS) cells have great potential in regenerative medicine

178 Given that both hES and iPS cells highly express mir-302, our findings suggest a

179 We employed human iPS cell (hiPSC) technology to generate RPE from BD pati

180 Human iPS cells hold great promise for disease modeling and tr

181 Human induced pluripotent stem (iPS) cells hold great promise for advancements in develo

182 Induced pluripotent stem (iPS) cells hold the potential to revolutionize regenerat

183 The generation of induced pluripotent stem (iPS) cells holds great promise in regenerative medicine.

184 reased L1 mobility in NHPs is not limited to iPS cells in culture and may have also occurred in the g

185 n the genetic programs of DE derived from ES/iPS cells in vitro and authentic DE from mouse embryos i

186 he neuronal lineage pathway compared with WT iPS cells in vitro and in vivo.

187 We generated mouse iPS cells in which expression of NKX2-5, an early cardia

188 yonic stem (ES) or induced pluripotent stem (iPS) cells in translational research.

189 hromosomal aberrations, compared to those in iPS cells induced only with 4 Yamanaka factors.

190 As the mechanism of conventional iPS cell induction methods remains largely unknown, unde

191 ent some of the earliest known regulators of iPS cell induction.

192 We hypothesized that iPS cells, injected into NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl

193 Focal benefit of iPS cell intervention translated into improved left vent

194 emoval enabled proficient differentiation of iPS cells into functional cardiac tissue.

195 ating embryonic or induced pluripotent stem (iPS) cells into beta-like-cells through endodermal proge

196 Analysis of iPS cells, iPS-derived neural stem cells (NSCs), neural

197 A cardinal feature of iPS cells is acquisition of indefinite self-renewal capa

198 Thus, to maintain the genetic stability of iPS cells is an important goal in iPS cell technology.

199 onal load acquired during gene correction of iPS cells is compatible with use in the treatment of gen

200 The generation of induced pluripotent stem (iPS) cells is an important tool for regenerative medicin

201 Lsh(-/-) MEFs into induced pluripotent stem (iPS) cells leads to increased neuronal lineage gene expr

202 formed to assess the genomic integrity of an iPS cell line after three sequential clonal events: init

203 aimed to generate a knock-in reporter human iPS cell line for MYF5, as an early myogenic specificati

204 een differentiated lineages from independent iPS cell lines and how similar iPS-CMs are to ES-CMs.

205 een differentiated lineages from independent iPS cell lines and, specifically, how similar iPS cell-d

206 eneration, genotyping and phenotyping of 711 iPS cell lines derived from 301 healthy individuals by t

207 es for generation of knock-in reporter human iPS cell lines for myogenic genes which can be used for

208 re importantly, the gene-corrected beta-Thal iPS cell lines from each patient can be induced to diffe

209 dentified possible loss of heterozygosity in iPS cell lines from one patient.

210 retention of PKD1 heterozygous mutations in iPS cell lines from two patients but identified possible

211 phenotypic characterization of many existing iPS cell lines limits their potential use for research a

212 egation of heteroplasmic mtDNA in individual iPS cell lines or mitochondrial replacement by SCNT in h

213 s and we further produced different isogenic iPS cell lines via gene editing.

214 Isogenic MELAS and Leigh syndrome iPS cell lines were generated containing exclusively wil

215 Here we have generated several human iPS cell lines, and we describe their pluripotent phenot

216 eviously derived human ES lines and 12 human iPS cell lines, and we have measured the in vitro differ

217 technology to develop endoderm-derived human iPS cell lines, together with other established cell lin

218 generate a library of patient-specific human iPS cell lines.

219 ed several mouse ES and induced pluripotent (iPS) cell lines expressing fluorescent proteins under re

220 ls, we established induced pluripotent stem (iPS) cell lines from fibroblasts of three ADPKD and two

221 mans, we generated induced pluripotent stem (iPS) cell lines from patients with Costello syndrome (CS

222 Multiple induced pluripotent stem (iPS) cell lines were derived from patients with common h

223 cell lines and 11 induced pluripotent stem (iPS) cell lines, from 38 laboratories worldwide, for gen

224 Thus, iPS cells may provide a novel approach to applying regen

225 tissue from patients into pluripotent stem (iPS) cells may now provide a general solution to this sh

226 Human induced pluripotent stem (iPS) cells now provide an opportunity for such research.

227 ative investigations of the quality of human iPS cells of different origins.

228 ities of primary neurons differentiated from iPS cells of human HD patients.

229 We generated cortical neurons from iPS cells of patients harboring alphasyn mutations, who

230 d patient-specific induced pluripotent stem (iPS) cells offer a unique approach to gene therapy.

231 Induced pluripotent stem (iPS) cells offer a unique potential for understanding th

232 nd for maintaining the pluripotency of these iPS cells on mitotically inactivated feeder layers prepa

233 s is true both of EBs made from the reporter iPS cells, or from an embryo-derived mouse ES line (R1 c

234 ind that 5-46% of the variation in different iPS cell phenotypes, including differentiation capacity

235 The whole protocol, encompassing human iPS cell preparation, autonomous differentiation, purifi

236 The generation of induced pluripotent stem (iPS) cells presents a challenge to normal developmental

237 Induced pluripotent stem (iPS) cells' promise may soon be realized in the field of

238 se donor cell identity and gradually acquire iPS cell properties.

239 onic stem (ES) and induced pluripotent stem (iPS) cells represent a potential source of megakaryocyte

240 Induced pluripotent stem cells (iPS cells) represent a unique tool for the study of the

241 Induced pluripotent stem (iPS) cells reprogrammed from somatic cells have the pote

242 hat Tet2 provides a mechanistic link between iPS cell reprogramming and B-cell transdifferentiation.

243 KM activation induces a 100-fold increase in iPS cell reprogramming efficiency, involving 95% of the

244 he context of most induced pluripotent stem (iPS) cell reprogramming methods, heterogeneous populatio

245 n vivo, we applied induced pluripotent stem (iPS) cell reprogramming of aged hematopoietic progenitor

246 nd participates in induced pluripotent stem (iPS) cell reprogramming.

247 is elevated during induced pluripotent stem (iPS) cell reprogramming.

248 Recent advances in induced pluripotent stem (iPS) cell research have significantly changed our perspe

249 that 2i/LIF treatment in clonal lines of pre-iPS cells results in the activation of endogenous Nanog

250 ve gene expression analysis of human and NHP iPS cells revealed differences in the regulation of long

251 n this protocol is followed, a proportion of iPS cells spontaneously form circular colonies, each of

252 ed genes are functionally associated with ES/iPS cell status while p53-activated genes are linked to

253 the manipulation of A3B and PIWIL2 levels in iPS cells supported a causal inverse relationship betwee

254 his Review, we describe the current state of iPS cell technology, including approaches by which they

255 ability of iPS cells is an important goal in iPS cell technology.

256 Induced pluripotent stem (iPS) cell technology holds vast promises for a cure to t

257 s play even wider roles in the generation of iPS cells than currently appreciated.

258 onic stem (ES) and induced pluripotent stem (iPS) cells that uses defined serum-free culture conditio

259 isease to generate induced pluripotent stem (iPS) cells that were differentiated to cardiomyocytes (i

260 sion in the undifferentiated state of ES and iPS cells, the variance narrows significantly in lineage

261 These findings confirm that iPS cells themselves may carry a significant mutational

262 ate the hurdles that must be overcome before iPS cell therapies will be available in clinics.

263 Local iPS cell therapy, but not delivery of parental fibroblas

264 ent state known as induced pluripotent stem (iPS) cells through overexpression of 4 transcription fac

265 We used patient-specific iPS cells to accurately reproduce the molecular and cell

266 To facilitate the transition of iPS cells to clinical practice, a variety of technologie

267 nd and transduction of the gene Foxp3 induce iPS cells to differentiate into Treg cells.

268 ncy were examined, along with the ability of iPS cells to differentiate, in vitro and in vivo, into d

269 These data underscore the potential of MPS-iPS cells to generate autologous hematopoietic grafts de

270 itors and allowed the resulting aged-derived iPS cells to reform hematopoiesis via blastocyst complem

271 d conditional expression of PAX7 in human ES/iPS cells to successfully derive large quantities of myo

272 onic stem (ES) and induced pluripotent stem (iPS) cells to cortical stem and progenitor cells, follow

273 onic stem (ES) and induced pluripotent stem (iPS) cells to identify Sox17 as a regulator of hemogenic

274 be generated from induced pluripotent stem (iPS) cells to provide an unlimited source of functional

275 g monocyte-derived induced pluripotent stem (iPS) cells to recapitulate disease-specific and normal m

276 hanced differentiation potential of Lsh(-/-) iPS cells toward the neuronal lineage pathway compared w

277 mouse models of type 1 and 2 diabetes via an iPS cell transplant.

278 gh temporal and spatial resolution, regional iPS cell transplantation restored, within 10 days post-i

279 Thus, in ischaemic cardiomyopathy, targeted iPS cell transplantation synchronized failing ventricles

280 rtantly, adoptive transfer of TCR-transduced iPS cells triggered infiltration of OVA-reactive CTLs in

281 er into recipient mice, the majority of OT-I/iPS cells underwent differentiation into CD8+ CTLs.

282 Generation of iPS cells using retroviral vectors from short- or long-t

283 emia major hydrops fetalis in transgene-free iPS cells using zinc finger-mediated insertion of a glob

284 ial stem cells from human ES cells and human iPS cells was dependent on retinoid signaling.

285 RDEB fibroblasts and keratinocytes into RDEB iPS cells was similar to that observed in wild-type (WT)

286 Using gut organoids derived from human iPS cells, we show that FOXO1 inhibition using a dominan

287 n model, within 30 min of coronary ligation, iPS cells were delivered to mapped infarcted areas.

288 ble expression in the fibroblasts from which iPS cells were derived.

289 More significantly, however, when these iPS cells were differentiated under conditions that prom

290 In vivo analyses showed that iPS cells were intrinsically able to differentiate into

291 ic stem (hES), and induced pluripotent stem (iPS) cells, were differentiated in vitro as a model to r

292 reprogramming into induced pluripotent stem (iPS) cells when co-expressed with the transcription fact

293 potential of human induced pluripotent stem (iPS) cells will require robust, precise and safe strateg

294 ally inherited Leigh syndrome (MILS) patient iPS cells with ATP synthase deficiency.

295 hocytes, generated induced pluripotent stem (iPS) cells with differentiation representing all 3 germ

296 es including human induced pluripotent stem (iPS) cells with improved efficiency.

297 erivation of human induced pluripotent stem (iPS) cells with similar properties as mouse iPS cells.

298 be reprogrammed to induced pluripotent stem (iPS) cells with substantially higher efficiencies than t

299 ighly expressed in induced pluripotent stem (iPS) cells, with no detectable expression in the fibrobl

300 nhances the generation of fully reprogrammed iPS cells without accelerating cell proliferation.